Search results for "From ACP Gastroenterology Monthly"

Semaglutide showed some benefit in patients with NASH, liver fibrosis

Significantly more patients taking the glucagon-like peptide-1 receptor agonist had resolution of their nonalcoholic steatohepatitis (NASH) than those taking placebo, but rates of liver fibrosis improvement were similar between groups, an industry-funded trial found.
https://diabetes.acponline.org/archives/2020/12/11/7.htm
11 Dec 2020